Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santen Pharmaceutical CoSNPHF +4.40%72 EV-to-OCF is 13.16 as of Aug. 14, 2026, which is 15% below its 10-year median of 15.44. GuruFocus rates SNPHF with a GF Score™ of 72/100 and a GF Value™ of $10.45 (Modestly Overvalued). Among 1,006 Drug Manufacturers companies, Santen Pharmaceutical Co ranks worse than 56.46% on this metric.
The historical rank and industry rank for Santen Pharmaceutical Co's EV-to-OCF or its related term are showing as below:
SNPHF'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.97 Med: 15.44 Max: 130.93
Current: 13.43
During the past 13 years, the highest EV-to-OCF of Santen Pharmaceutical Co was 130.93. The lowest was 5.97. And the median was 15.44.
SNPHF's EV-to-OCF is ranked worse than 56.46% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.045
vs SNPHF: 13.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Santen Pharmaceutical Co (OTCPK:SNPHF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Santen Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Santen Pharmaceutical Co's share price for today is $13.05.
Santen Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.761.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Santen Pharmaceutical Co EV-to-OCF Related Terms
Santen Pharmaceutical Co EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's EV-to-OCF falls into.
Santen Pharmaceutical Co's current Enterprise Value is $3,447 Mil.
Santen Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $262 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHF) has a EV-to-OCF of 13.16 as of Aug. 14, 2026. This is 15% below median its historical median of 15.44. Over the past decade, Santen Pharmaceutical Co's EV-to-OCF has ranged from 5.97 to 130.93. According to the industry distribution chart, Santen Pharmaceutical Co ranks #568 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is Santen Pharmaceutical Co's EV-to-OCF too high?
Santen Pharmaceutical Co's current EV-to-OCF of 13.16 is 15% below median its 10-year median of 15.44. Over the past 10 years, this metric has ranged from a low of 5.97 to a high of 130.93. The Drug Manufacturers industry median EV-to-OCF is 11.05. Santen Pharmaceutical Co's value of 13.16 is 19.1% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #568 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #568 out of 1006 companies for EV-to-OCF. This places Santen Pharmaceutical Co in the lower half of its industry. The industry median EV-to-OCF is 11.05. Santen Pharmaceutical Co's value of 13.16 is 19.1% above this benchmark. Historically, Santen Pharmaceutical Co's own EV-to-OCF has ranged from 5.97 to 130.93 over the past decade. While the company's 10-year median is 15.44 vs. the industry median of 11.05, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current EV-to-OCF of 13.16 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current EV-to-OCF is 13.16, which is 15% below median its own 10-year median of 15.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $13.05 — trading 24.9% above its estimated fair value. The current EV-to-OCF is 13.16, which is 15% below median its 10-year median of 15.44 and 19.1% above the Drug Manufacturers industry median of 11.05. Santen Pharmaceutical Co's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current EV-to-OCF is 13.16 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 24.9% above its estimated GF Value™ of $10.45.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHF:
EV-to-OCF: 13.16 (15% below median its 10-year median of 15.44)
GF Value™: $10.45 vs. price of $13.05 (24.9% above fair value)
Industry Position: 19.1% above the Drug Manufacturers median (#568 of 1006)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
72GF Score
Get the complete analysis for SNPHF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
